Side-by-side · Research reference

MT-1vsPEG-MGF

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED9/51 cited

BAnimal-MechanisticHUMAN-REVIEWED2/69 cited

MT-1

α-MSH Analogue · FDA-Approved

16 mgImplant dose

13 AAPeptide lengthChawathe 2026

2019FDA approval

SQ Implant · 60-Day Release

PEG-MGF

IGF-1Ec Splice Variant · PEGylated

~2 hrHalf-life (PEG)

~7 minNative MGF t½

IGF-1EcSplice variant

SQ · Research Protocol

01Mechanism of Action

Parameter

MT-1

PEG-MGF

Primary target

Melanocortin-1 receptor (MC1R) on melanocytesLangan 2010

IGF-1 receptor on muscle satellite cells and myocytes

Pathway

α-MSH analogue → MC1R activation → cAMP elevation → MITF transcription → eumelanin synthesis

IGF-1R → PI3K/Akt → mTOR activation → Satellite cell proliferation & myoblast fusion

Downstream effect

Increased melanogenesis, photoprotection, reduced UV sensitivityLangan 2010

Satellite cell activation, muscle fiber repair, localized hypertrophy signaling

Feedback intact?

Yes — exogenous MC1R agonism does not suppress endogenous α-MSH production

Partially bypassed — does not require hepatic IGF-1 synthesis

Origin

Synthetic 13-AA peptidomimetic with norleucine (position 4) and D-phenylalanine (position 7) substitutions for metabolic stabilityChawathe 2026

IGF-1Ec splice variant (exon 4–6) conjugated to polyethylene glycol for extended circulation

Antibody development

—

Unknown — no long-term human immunogenicity data

02Dosage Protocols

Parameter

MT-1

PEG-MGF

Standard dose

16 mg subcutaneous implant

FDA-approved formulation (Scenesse).

—

Frequency

Every 60 days

Sustained release implant — no daily administration required.

Post-training or daily

Timing to match endogenous MGF pulse post-exercise.

Evidence basis

Phase 3 RCT / FDA-approved orphan drug

Animal / mechanistic

Indication

Erythropoietic protoporphyria (EPP)

Narrow FDA approval — not licensed for cosmetic tanning.

—

Duration

Seasonal use (spring–autumn typical)

Aligned with peak UV exposure months.

—

Route

Subcutaneous implant — upper arm or abdomen

—

Stability

Norleucine/D-Phe substitutions enhance peptidase resistance

Modified structure vs endogenous α-MSH (Met⁴, L-Phe⁷).

—

Research dose range

—

100–200 mcg

Extrapolated from animal models; no validated human protocols.

Half-life

—

~2 hours (PEGylated)

Native MGF: ~7 min; PEGylation extends circulation.

Reconstitution

—

Sterile bacteriostatic water

Lyophilized form; store reconstituted at 2–8 °C.

PEG molecular weight

—

Typically 5–30 kDa

Higher MW = longer t½, greater steric hindrance.

Timing

—

Within 30–60 min post-training

Aligns with endogenous MGF window.

03Metabolic / Fat Loss Evidence

Parameter

MT-1

PEG-MGF

Primary target

—

Muscle tissue (satellite cells, myocytes) — not adipose-specific

Indirect metabolic effect

—

IGF-1 signaling may modulate insulin sensitivity and lipid metabolismRen 2015

Mechanism distinct from direct lipolytic peptides.

Body composition

—

Lean mass preservation / hypertrophy focus

Fat loss evidence

—

No direct human or animal RCT data for PEG-MGF-driven fat reduction

04Side Effects & Safety

Parameter

MT-1

PEG-MGF

Nausea

Common (>10%) — mild, transient

—

Implant site reaction

Erythema, bruising, tenderness at insertion site

—

Hyperpigmentation

Generalised tanning (therapeutic effect), darkening of freckles/neviLangan 2010 Habbema 2017

Expected melanogenic response — complicates pigmented lesion surveillance.

—

Melanocytic changes

Rapid pigmentation of existing nevi; new melanocytic lesions reported with unregulated useHabbema 2017

Requires dermatologic monitoring; theoretical melanoma concern with chronic stimulation.

—

Headache

Occasional (MC1R-independent melanocortin effects)

—

Photosensitivity (paradoxical)

Rare phototoxic reactions despite melanin increase

—

Contamination risk (unregulated)

Impurity, infection, blood-borne virus transmission from illicit melanotan productsLangan 2010 Habbema 2017

Applies to internet/gym-sourced 'melanotan' — not FDA-approved Scenesse.

—

Injection site reaction

—

Erythema, induration (common with SQ peptides)

Hypoglycemia risk

—

IGF-1 axis activation can lower blood glucose

IGF-1R overstimulation

—

Theoretical risk of aberrant cell proliferation with chronic supraphysiological exposure

Fluid retention

—

Possible with IGF-1 pathway activation (dose-dependent)

PEG accumulation

—

Chronic high-dose PEGylated proteins may accumulate in tissues; clearance slower in renal impairment

Antibody formation

—

PEGylated proteins can elicit anti-PEG antibodies (neutralizing potential unknown)

Cancer risk

—

IGF-1 axis stimulation contraindicated in active malignancy

Human safety data

—

Absent — no published human trials for PEG-MGF

Absolute Contraindications

MT-1

·Hypersensitivity to afamelanotide or excipients
·Hepatic impairment (no safety data)
·Renal impairment (no safety data)

PEG-MGF

·Active malignancy or history of cancer (IGF-1R proliferative signaling)
·Known hypersensitivity to PEGylated compounds
·Pregnancy / lactation (no reproductive toxicity data)

Relative Contraindications

MT-1

·History of melanoma or atypical nevi (melanocortin receptor stimulation concern)Habbema 2017
·Pregnancy/lactation (insufficient data)
·Photosensitive dermatoses (other than EPP)

PEG-MGF

·Diabetes (monitor glucose closely)
·Renal impairment (PEG clearance reduced)
·Retinopathy (IGF-1 axis effects on vascular proliferation)

05Administration Protocol

Parameter

MT-1

PEG-MGF

1. Implant insertion

Performed by trained healthcare provider. Sterile technique. Small incision in upper arm (triceps) or lower abdomen using trocar. 16 mg rod (4 mm × 1.5 cm) inserted subcutaneously.

Add 1–2 mL bacteriostatic water to lyophilized vial. Swirl gently — do not shake. Solution should be clear to slightly opalescent.

2. Site care

Pressure applied post-insertion. Sterile dressing × 24 hrs. Avoid strenuous activity for 24–48 hrs to prevent extrusion.

Subcutaneous — abdomen or thigh. Rotate sites to avoid lipodystrophy. Avoid areas with scar tissue or active inflammation.

3. Release kinetics

Slow biodegradable polymer matrix releases afamelanotide over 60 days, maintaining therapeutic plasma levels without daily dosing.

Post-training preferred (within 30–60 min) to align with endogenous MGF expression window. Alternatively, daily morning dose on non-training days.

4. Repeat dosing

New implant every 60 days during high UV season (spring–autumn in temperate climates). Rotate implant sites to avoid scarring.

Lyophilized: room temperature, light-protected, desiccated. Reconstituted: refrigerate 2–8 °C, use within 14–21 days.

5. Monitoring

Baseline and periodic dermatologic exams to document pigmented lesions. Patient education on self-examination for new/changing nevi.

29–31G insulin syringe, 8–12 mm length. Pinch skin fold, insert at 45° angle for subcutaneous delivery.

06Stack Synergy

MT-1

— no documented stacks

PEG-MGF

+ BPC-157

Moderate

View BPC-157 →

BPC-157 promotes angiogenesis and tendon/ligament repair via VEGF and growth factor modulation, while PEG-MGF targets satellite cell activation and myocyte proliferation. Complementary pathways for comprehensive tissue repair post-injury or intensive training. BPC-157's systemic stability and oral bioavailability contrast with PEG-MGF's localized IGF-1R signaling.

PEG-MGF: 100–200 mcg SQ post-training
BPC-157: 250–500 mcg SQ or oral, twice daily
Duration: 4–6 weeks (injury-dependent)
Primary benefit: Accelerated muscle and connective tissue repair, enhanced recovery

+ TB-500

Strong

View TB-500 →

TB-500 (Thymosin Beta-4 fragment) upregulates actin polymerization, cell migration, and anti-inflammatory pathways, while PEG-MGF drives satellite cell proliferation via IGF-1R/mTOR. Synergistic for muscle regeneration: TB-500 mobilizes progenitor cells, PEG-MGF stimulates their differentiation into myocytes. Both have overlapping but distinct repair cascades.

PEG-MGF: 100–200 mcg SQ post-training
TB-500: 2–5 mg SQ, 2× per week (loading), then weekly
Timing: Stagger injections by 6–12 hours
Primary benefit: Maximal satellite cell recruitment and myogenic differentiation, injury repair